Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Rosetta Genomics's Total Stockholders Equity for the quarter that ended in Jun. 2017 was $1.10 Mil. Rosetta Genomics's Total Assets for the quarter that ended in Jun. 2017 was $6.21 Mil.
Therefore, Rosetta Genomics's Equity to Asset Ratio for the quarter that ended in Jun. 2017 was 0.18.
The historical rank and industry rank for Rosetta Genomics's Equity-to-Asset or its related term are showing as below:
ROSGQ's Equity-to-Asset is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 0.59 * Ranked among companies with meaningful Equity-to-Asset only.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Rosetta Genomics Equity-to-Asset Related Terms
Rosetta Genomics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Rosetta Genomics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROSGQ vs TEAR, IDTA, ABMC: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, Rosetta Genomics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rosetta Genomics Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Rosetta Genomics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Rosetta Genomics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2016 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rosetta Genomics (ROSGQ) has a Equity-to-Asset of 0.18 as of Jun. 2017. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Rosetta Genomics and its competitors.
Is Rosetta Genomics' Equity-to-Asset too high?
Rosetta Genomics' current Equity-to-Asset is 0.18. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.59. Rosetta Genomics' value of 0.18 is 69.5% below this industry median.
How does Rosetta Genomics' Equity-to-Asset compare to TEAR and IDTA?
Rosetta Genomics' Equity-to-Asset of 0.18 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Equity-to-Asset is 0.59. Rosetta Genomics' value of 0.18 is 69.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.59, based on 210 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rosetta Genomics's current Equity-to-Asset of 0.18 is 69.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Rosetta Genomics and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rosetta Genomics's current Equity-to-Asset is 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current Equity-to-Asset of 0.18. The current Equity-to-Asset is 0.18 and 69.5% below the Medical Diagnostics & Research industry median of 0.59. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current Equity-to-Asset is 0.18 as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROSGQ has been successfully added to your 
